Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Mirjam Renovanz , Sylvia C Kurz , Johannes Rieger , Bianca Walter , Hannes Becker , Hanni Hille , Paula Bombach , David Rieger , Lucia Grosse , Lara Häusser , Marco Skardelly , Daniel J Merk , Frank Paulsen , Elgin Hoffmann , Cihan Gani , Manuela Neumann , Rudi Beschorner , Olaf Rieß , Cristiana Roggia , Christopher Schroeder , Stephan Ossowski , Sorin Armeanu-Ebinger , Axel Gschwind , Saskia Biskup , Martin Schulze , Falko Fend , Stephan Singer , Lars Zender , Claudia Lengerke , Sara Yvonne Brucker , Tobias Engler , Andrea Forschner , Arnulf Stenzl , Oliver Kohlbacher , Sven Nahnsen , Gisela Gabernet , Sven Fillinger , Benjamin Bender , Ulrike Ernemann , Öznur Öner , Janina Beha , Holly Sundberg Malek , Yvonne Möller , Kristina Ruhm , Marcos Tatagiba , Jens Schittenhelm , Michael Bitzer , Nisar Malek , Daniel Zips , Ghazaleh Tabatabai Neuro-oncology advances（2023）
摘要
Our study supports the clinical utility of biomarker-guided therapies for neuro-oncology patients and indicates clinical benefit in a subset of patients. Our data might inform future clinical trials, translational studies, and even clinical care.
更多 查看译文
关键词
MTB@ZPM-001 (NCT03503149), Molecular tumor board, precision medicine, real-world data, targeted therapy
AI 理解论文
溯源树
样例
